Influenza Other Respir Viruses
November 2024
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.
View Article and Find Full Text PDFWe aimed to estimate the impact of influenza vaccination in the Netherlands using general practitioner medical records for 2011-2020. We found that vaccinees had higher consultation rates for influenza-like-illness, acute respiratory infections, and pneumonia, as well as antibiotic use, hospitalisations, and several control diagnoses (i.e.
View Article and Find Full Text PDF